Aquestive Therapeutics Inc (AQST)
3.10
-0.18
(-5.49%)
USD |
NASDAQ |
May 17, 16:00
3.10
0.00 (0.00%)
After-Hours: 20:00
Aquestive Therapeutics Enterprise Value: 216.71M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 216.71M |
| May 16, 2024 | 232.19M |
| May 15, 2024 | 226.73M |
| May 14, 2024 | 224.91M |
| May 13, 2024 | 231.28M |
| May 10, 2024 | 214.89M |
| May 09, 2024 | 233.10M |
| May 08, 2024 | 214.44M |
| May 07, 2024 | 241.29M |
| May 06, 2024 | 252.22M |
| May 03, 2024 | 254.04M |
| May 02, 2024 | 232.19M |
| May 01, 2024 | 239.93M |
| April 30, 2024 | 239.47M |
| April 29, 2024 | 273.61M |
| April 26, 2024 | 304.11M |
| April 25, 2024 | 291.36M |
| April 24, 2024 | 288.63M |
| April 23, 2024 | 323.23M |
| April 22, 2024 | 332.33M |
| April 19, 2024 | 305.00M |
| April 18, 2024 | 340.74M |
| April 17, 2024 | 288.26M |
| April 16, 2024 | 281.92M |
| April 15, 2024 | 290.07M |
| Date | Value |
|---|---|
| April 12, 2024 | 287.35M |
| April 11, 2024 | 303.64M |
| April 10, 2024 | 301.83M |
| April 09, 2024 | 303.64M |
| April 08, 2024 | 301.83M |
| April 05, 2024 | 304.54M |
| April 04, 2024 | 309.97M |
| April 03, 2024 | 329.88M |
| April 02, 2024 | 308.16M |
| April 01, 2024 | 307.26M |
| March 31, 2024 | 319.02M |
| March 28, 2024 | 386.92M |
| March 27, 2024 | 372.53M |
| March 26, 2024 | 368.93M |
| March 25, 2024 | 379.72M |
| March 22, 2024 | 397.72M |
| March 21, 2024 | 324.72M |
| March 20, 2024 | 333.88M |
| March 19, 2024 | 395.09M |
| March 18, 2024 | 407.55M |
| March 15, 2024 | 450.06M |
| March 14, 2024 | 388.49M |
| March 13, 2024 | 402.42M |
| March 12, 2024 | 377.49M |
| March 11, 2024 | 365.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
62.73M
Minimum
Mar 16 2020
450.06M
Maximum
Mar 15 2024
157.72M
Average
144.27M
Median
Enterprise Value Benchmarks
| Lifecore Biomedical Inc | -- |
| Harrow Inc | 700.82M |
| Akebia Therapeutics Inc | 229.22M |
| 89bio Inc | 311.72M |
| Humacyte Inc | 638.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.83M |
| Revenue (Quarterly) | 12.05M |
| Total Expenses (Quarterly) | 21.01M |
| EPS Diluted (Quarterly) | -0.17 |
| Gross Profit Margin (Quarterly) | 63.59% |
| Profit Margin (Quarterly) | -106.4% |
| Earnings Yield | -13.96% |
| Normalized Earnings Yield | -13.57 |